

Revision date 12-Sep-2023 Version 2.01 Page 1/11

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Pfizer-BioNTech Covid-19 vaccine Tris-Sucrose Omicron XBB.1.5 Variant **Product Name**

Product Code(s) PF00663 **Form** nanoform

Synonyms Pfizer-BioNTech Covid-19 vaccine for ages 12 and older: Ready to use, Grey Cap;

Pfizer-BioNTech Covid-19 vaccine for ages 5 through 11: 5 to 11, Ready to use, Blue Cap; Pfizer-BioNTech Covid-19 vaccine for ages 6m through 4: Dilute to use, Yellow Cap; PF-07302048 containing PF-07963164 (BNT162b2): Covid19 Tris Formulation;

PF-07302048 containing PF-07963164 (BNT162b2); CorVAC Containing PF-07963164 (BNT162b2); CoVVAC Containing PF-07963164 (BNT162b2); COVID Vaccine Containing PF-07963164 (BNT162b2); COVID-19 Vaccine Containing PF-07963164 (BNT162b2);

Comirnaty **Trade Name:**

Lipid Nanoparticles containing PF-07963164 (BNT162b2) and Lipids **Chemical Family:**

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product

1.3. Details of the supplier of the safety data sheet

Pfizer Ireland Pharmaceuticals Pfizer Inc

66 Hudson Boulevard East **OSG** Building

New York, New York 10001 Ringaskiddy, Co. Cork. 1-800-879-3477

Ireland

+353 21 4378701

pfizer-MSDS@pfizer.com E-mail address

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous according to Regulation (EC) 1272/2008 and/or other applicable regulations.

2.2. Label elements

Signal word Not classified

Hazard statements Not classified in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients

(see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which

Product Name Pfizer-BioNTech Covid-19 vaccine Tris-Sucrose Omicron XBB.1.5 Variant Revision date 12-Sep-2023

Revision date 12-Sep-2023 Version 2.01

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Page 2/11

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances Not applicable

3.2 Mixtures

NonHazardous

Noninazaruous							
Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified as hazardous	Not Listed	No data available	No data available
Sucrose (CAS #: 57-50-1)	< 10	-	200-334-9	Not classified as hazardous	Not Listed	No data available	No data available
ALC-0315 (CAS #: 2036272-55-4)	< 2	-	Not Listed	Not classified as hazardous	Not Listed	No data available	No data available
Tromethamine (CAS #: 77-86-1)	*	-	201-064-4	Not classified as hazardous	Not Listed	No data available	No data available
Tris(hydroxymethyl)a minomethane hydrochloride (CAS #: 1185-53-1)	*	-	214-684-5	Not classified as hazardous	Not Listed	No data available	No data available
PF-07963164 (CAS #: -)	< 1		Not Listed	Not classified as hazardous	Not Listed	No data available	No data available
Cholesterol (CAS #: 57-88-5)	< 1	-	200-353-2	Not classified as hazardous	Not Listed	No data available	No data available
ALC-0159 (CAS #: 1849616-42-7)	< 1	-	Not Listed	Not classified as hazardous	Not Listed	No data available	No data available
1,2-Distearoyl-sn-glyc ero-3-phosphocholine (CAS #: 816-94-4)	< 1	-	212-440-2	Not classified as hazardous	Not Listed	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4	Inhalation LC50 - 4	Inhalation LC50 - 4
			hour - dust/mist -	hour - vapor - mg/L	hour - gas - ppm
			mg/L		
Water	89838.9	No data available	No data available	No data available	No data available
7732-18-5					
Sucrose	29700	No data available	No data available	No data available	No data available
57-50-1					

Product Name Pfizer-BioNTech Covid-19 vaccine Tris-Sucrose Omicron

XBB.1.5 Variant

Revision date 12-Sep-2023 Version 2.01

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	
Tromethamine 77-86-1	5900	5000	No data available	No data available	No data available
Cholesterol 57-88-5	No data available	2000	No data available	No data available	No data available

Additional information - Not Assigned

* Proprietary

secret.

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade

Page 3/11

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation Remove to fresh air. Seek immediate medical attention/advice.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

Consult a physician.

Skin contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion Never give anything by mouth to an unconscious person. Wash out mouth with water. Do

not induce vomiting unless directed by medical personnel. Seek medical attention

immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and

effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the

chemical

Fine particles (such as mists) may fuel fires/explosions.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for

fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

Use personal protection equipment.

Page 4/11

Product Name Pfizer-BioNTech Covid-19 vaccine Tris-Sucrose Omicron XBB.1.5 Variant

Revision date 12-Sep-2023

Version 2.01

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be

taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean Methods for cleaning up

spill area thoroughly.

Clean contaminated objects and areas thoroughly observing environmental regulations. Prevention of secondary hazards

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Restrict access to work area. A change area to facilitate 'good laboratory/manufacturing' decontamination practices is recommended. Additional controls (based on risk assessment) should be implemented where open handling is required. Use enclosed manufacturing processing strategies. Avoid inhalation and contact with skin, eye, and clothing. Wash hands and any exposed skin after removal of PPE. When handling, use appropriate personal protective equipment (see Section 8). Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Store as directed by product packaging. **Storage Conditions**

7.3. Specific end use(s)

Specific use(s) Vaccine.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Sucrose

ACGIH TLV 10 mg/m³ Bulgaria 10.0 mg/m³ Estonia 10 mg/m³ France 10 mg/m³

Product Name Pfizer-BioNTech Covid-19 vaccine Tris-Sucrose Omicron

XBB.1.5 Variant

Revision date 12-Sep-2023 Version 2.01

revision when new information becomes available.

Ireland 10 mg/m³

STEL: 20 mg/m³

5 mg/m³ Latvia Spain 10 mg/m³ **OSHA PEL** 15 mg/m³ 5 mg/m³

(vacated) TWA: 15 mg/m3 total dust

(vacated) TWA: 5 mg/m3 respirable fraction

Page 5/11

United Kingdom TWA: 10 mg/m³ STEL: 20 mg/m³

(OEB) Statement:

Pfizer Occupational Exposure Band The Vaccines Occupational Exposure Band (V-OEB) is a classification that has been assigned to biotechnology-based vaccines and antigen components. Risk assessments should be performed to assess potential exposures and determine appropriate controls. The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to

ALC-0315

Pfizer Occupational Exposure

Band (OEB):

OEB 3 - Contact Hazards Unknown (control exposure to the range of 10ug/m3 to <

100ug/m³)

Tromethamine

Pfizer Occupational Exposure

Band (OEB):

OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

ALC-0159

Pfizer Occupational Exposure

Band (OEB):

OEB 3 - Contact Hazards Unknown (control exposure to the range of 10ug/m3 to <

100ug/m3)

PF-07963164

Pfizer Occupational Exposure

Band (OEB):

V-OEB

PF-07302048

Pfizer Occupational Exposure

Band (OEB):

V-OEB

8.2. Exposure controls

Engineering controls

Release prevention and exposure protection measures should be established for any activities involving this material, as determined by a risk assessment conducted using appropriate Occupational Hygiene Risk Assessment tools. The containment level required for the activity should be based on the conclusions of the risk assessment. Where warranted, engineering controls, such as biosafety cabinets, should be applied as the primary means to control exposures.

Environmental exposure controls

No information available.

Personal protective equipment

Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Eye/face protection

Wear safety glasses as minimum protection (goggles recommended). (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Wear impervious disposable gloves (e.g. Nitrile, etc.) as minimum protection (double recommended). (Protective gloves must meet the standards in accordance with EN374,

ASTM F1001 or international equivalent.).

Product Name Pfizer-BioNTech Covid-19 vaccine Tris-Sucrose Omicron

XBB.1.5 Variant

Revision date 12-Sep-2023 Version 2.01

Skin and body protectionWear impervious disposable protective clothing when handling this compound. Full body

protection is recommended (scale dependent). (Protective clothing must meet the standards

Page 6/11

in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection If operating and handling conditions result in airborne exposure, wear an appropriate

respirator with a protection factor sufficient to control exposures (e.g. particulate cartridge with a full face respirator, P3 filter). (Respirators must meet the standards in accordance

with EN136, EN143, ASTM F2704-10 or international equivalent.)

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state Liquid Color White milky

Odor No information available.
Odor threshold No information available

Molecular formulaMixtureMolecular weightMixture

<u>Property</u> <u>Values</u>

pHNo data availableMelting point / freezing pointNo data available

Boiling point / boiling range

Flash point

Evaporation rate

Flammability (solid, gas)

No information available
No data available
No data available

Flammability Limit in Air

Upper flammability limit: No data available

Lower flammability limit: No data available

Vapor pressure No data available Vapor density No data available Relative density No data available Water solubility No data available Solubility(ies) No data available Partition coefficient No data available **Autoignition temperature** No data available **Decomposition temperature** No data available Kinematic viscosity No data available Dynamic viscosity No data available

Particle characteristics

Particle SizeNo information availableParticle Size DistributionNo information availableExplosive propertiesNo information available

Partition Coefficient: (Method, pH, Endpoint, Value)

Tromethamine

Predicted 7.4 Log D -4.668

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

Page 7/11

Product Name Pfizer-BioNTech Covid-19 vaccine Tris-Sucrose Omicron XBB.1.5 Variant

Revision date 12-Sep-2023 Version 2.01

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability
Stability

Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available. Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep

away from heat sources and electrostatic discharge.

10.5. Incompatible materials

Incompatible materials

As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: Toxicological properties have not been thoroughly investigated. The following information is

available for the individual ingredients.

Short term In the event of accidental injection, an allergic reaction may occur. If an allergic reaction

occurs, the worker should be removed to the nearest emergency room and the appropriate

therapy instituted.

Known Clinical Effects: Based on clinical trials in humans, possible adverse effects following intravenous exposure

to this compound may include: injection site pain, muscle pain, headache, fever, chills, tiredness, joint pain, abnormal redness of skin (erythema), and sleep disturbances. Serious

allergic reactions, including anaphylaxis, have been reported.

Acute toxicity Based on available data, the classification criteria are not met.

Serious eye damage/eye irritation Based on available data, the classification criteria are not met.

Skin corrosion/irritation
Respiratory or skin sensitization
STOT - single exposure
STOT - repeated exposure
STOT - repeated exposure
STOT - repeated exposure
STOT - repeated exposure
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.

Germ cell mutagenicity

Carcinogenicity

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Sucrose

Rat Oral LD 50 29,700 mg/kg

Tromethamine

Rat Oral LD50 5900 mg/kg

Rat Dermal LD 50 > 5000 mg/kg

Page 8/11

Product Name Pfizer-BioNTech Covid-19 vaccine Tris-Sucrose Omicron

XBB.1.5 Variant

Revision date 12-Sep-2023 Version 2.01

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Sucrose	= 29700 mg/kg (Rat)	-	-
Tromethamine	= 5900 mg/kg (Rat)	> 5000 mg/kg (Rat)	-
Cholesterol		> 2000 mg/kg (Rat)	-

Irritation / Sensitization: (Study Type, Species, Severity)

Tromethamine

Eye Irritation Rabbit Slight Skin Irritation Rabbit Slight

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

PF-07302048

4 Week(s) Rat Intramuscular * 10 μg LOAEL Skin, Blood forming organs, Blood, Skeletal muscle, Lymphoid tissue, Spleen Repeated Dose Toxicity Comments: PF-07302048: * Doses were administered once a week.

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Tromethamine

Bacterial Mutagenicity (Ames) E. coli Negative

Carcinogenicity See below

Cholesterol

IARC Group 3 (Not Classifiable)

Data for the Drug Product

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should

be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Tromethamine

Daphnia magna (Water Flea) OECD EC50 48 hours > 980 mg/L

Pseudokirchneriella subcapitata (Green Alga) OECD EC50 48 Hours 473 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Tromethamine

Activated sludge OECD EC50 > 1000 mg/L

12.2. Persistence and degradability

Persistence and degradability No information available.

Page 9/11

Product Name Pfizer-BioNTech Covid-19 vaccine Tris-Sucrose Omicron XBB.1.5 Variant Revision date 12-Sep-2023

Revision date 12-Sep-2023 Version 2.01

12.3. Bioaccumulative potential

Bioaccumulation

Partition Coefficient: (Method, pH, Endpoint, Value)

Tromethamine

Predicted 7.4 Log D -4.668

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Tromethamine	The substance is not PBT / vPvB PBT assessment does
	not apply
Tris(hydroxymethyl)aminomethane hydrochloride	The substance is not PBT / vPvB PBT assessment does
	not apply
Cholesterol	The substance is not PBT / vPvB

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:
UN proper shipping name:
Transport hazard class(es):
Packing group:
Environmental Hazard(s):
Not applicable
Not applicable
Not applicable

Special precautions for user: Not applicable

Page 10 / 11

SAFETY DATA SHEET Product Name Pfizer-BioNTech Covid-19 vaccine Tris-Sucrose Omicron

Revision date 12-Sep-2023 Version 2.01

Section 15: REGULATORY INFORMATION

XBB.1.5 Variant

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water	
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Sucrose	Not Listed Not Listed Present 231-791-2 Present
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS ALC-0315	Not Listed Not Listed Present 200-334-9 Present
CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS Tromethamine	Not Listed Not Listed Not Listed
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Not Listed Not Listed Present 201-064-4 Present Schedule 4
Tris(hydroxymethyl)aminomethane hydrochloride CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS	Not Listed Not Listed Present 214-684-5 Present
PF-07963164 CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS Chelesters	Not Listed Not Listed Not Listed
Cholesterol CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Standard for Uniform Scheduling of Medicines and Poisons (SUSMP) ALC-0159	Not Listed Not Listed Present 200-353-2 Present Schedule 4
CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS 1,2-Distearoyl-sn-glycero-3-phosphocholine CERCLA/SARA Section 313 de minimus % California Proposition 65	Not Listed Not Listed Not Listed Not Listed Not Listed
EINECS	212-440-2

Page 11/11

Product Name Pfizer-BioNTech Covid-19 vaccine Tris-Sucrose Omicron XBB.1.5 Variant

Revision date 12-Sep-2023 Version 2.01

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Plant protection products directive (91/414/EEC)

Trail protection products directive (31/414/LLO)				
Chemical name	Plant protection products directive (91/414/EEC)			
Sucrose - 57-50-1	Plant protection agent			

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the

Company/Undertaking.

Revision date 12-Sep-2023

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

PF00663 PP-CVV-USA-3261